NIKKEI 225
39,087.56 +470.46 (+1.22%) HANG SENG
18,908.98 -286.62 (-1.49%) CRUDE OIL
77.04 -0.53 (-0.68%) GOLD FUTURES
2,373.80 -19.10 (-0.80%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,531.95 -344.24 (-0.63%)
Addex Therapeutics Ltd (ADXN.SW)
| Previous close | 0.0650 |
| Open | 0.0652 |
| Bid | 0.0670 x 0 |
| Ask | 0.0680 x 0 |
| Day's range | 0.0652 - 0.0670 |
| 52-week range | 0.0362 - 0.2600 |
| Volume | |
| Avg. volume | 1,274,972 |
| Market cap | 8.721M |
| Beta (5Y monthly) | 1.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 18 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAddex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and d
- GlobeNewswire
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Pha
Globe NewswireAddex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporat
